Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas

Cancer Research

Volumn 72, Issue 1, 2012, Pages 100-111

  Okayama, Hirokazu ^a,e   Kohno, Takashi ^a   Ishii, Yuko ^a   Shimada, Yoko ^a   Shiraishi, Kouya ^a   Iwakawa, Reika ^a   Furuta, Koh ^b   Tsuta, Koji ^b   Shibata, Tatsuhiro ^a   Yamamoto, Seiichiro ^c   Watanabe, Shun Ichi ^b   Sakamoto, Hiromi ^a   Kumamoto, Kensuke ^e   Takenoshita, Seiichi ^e   Gotoh, Noriko ^d   Mizuno, Hideaki ^f,g   Sarai, Akinori ^f   Kawano, Shuichi ^d   Yamaguchi, Rui ^d   Miyano, Satoru ^d   Yokota, Jun ^a   more..

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN; RNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DEPDC1 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; GRIN2A GENE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; ONCOGENE; ONCOGENE ALK; ONCOGENE EGFR; ONCOGENE K RAS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE EXPRESSION PROFILING; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 84855369366     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1403     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
3. Colvy T, Noguchi M, Henschke C, Vazquez M, Geisinger K, Yokose T, et al. Adenocarcinoma. In:Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: pathology and genetics; tumours of the lung, pleura, thymus and heart. IARC Press: Lyon, France; 2004. p. 35-44.
4. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80.
5. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med 2008;359:1367-80.
6. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-14.
7. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, et al. 2288; Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010;36 Suppl 3:S21-9.
8. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010;18:548-51.
9. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-90. (Pubitemid 47463669)
10. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
12. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55. (Pubitemid 47019443)
13. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
14. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-88. (Pubitemid 46622139)
15. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008;214:347-56. (Pubitemid 351212390)
16. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-27.
17. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-26. (Pubitemid 46211346)
18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: pathology and genetics; tumours of the lung, pleura, thymus and heart. IARC Press: Lyon, France; 2004. p. 1-344.
19. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011;17:1875-82.
20. Robins JM, Gail MH, Lubin JH. More on "Biased selection of controls for case-control analyses of cohort studies". Biometrics 1986;42:293-9.
21. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8. Available from: http://rana.lbl.gov/eisen/.
23. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
24. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385-90. (Pubitemid 47510364)
25. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24.
26. Mizuno H, Kitada K, Nakai K, Sarai A. 2288; PrognoScan: a new database for meta-analysis of the prognostic value of genes. 2288; BMC Med Genomics 2009;2:18. Available from: http://gibk21.bio.kyutech.ac.jp/PrognoScan/index. html.
27. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-6.
28. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010;29:49-60.
29. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
30. Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional upregulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-8.
31. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-71.
32. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009;27:2793-9.
33. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 2010;42:1021-6.
34. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-6.
35. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 2007;26:6448-55. (Pubitemid 47494219)
36. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res 2010;70:5829-39.
37. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer 2011;10:15.